Skip to content

Forearm immobilization in T2D (FIT2D)

The impact of short-term forearm immobilization on forearm muscle glucose and amino acid metabolism of volunteers with or without type 2 diabetes - Forearm immobilization in T2D (FIT2D)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57111
Enrollment
26
Registered
2024-07-15
Start date
2024-11-21
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insulin sensitivity, muscle loss, muscle disuse

Interventions

Participants with and without T2D will undergo 2 days of forearm immobilization as a model of local physical inactivity. Before, throughout, and after immobilization arteriovenous forearm balance me

Sponsors

Wageningen Universiteit
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Males and females with or without diagnosed type 2 diabetesUse lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2DAged 18-80 years at the time of signing informed consent18.5 = BMI = 35 kg·m2

Exclusion criteria

Exclusion criteria: Type 1 or a genetic form of diabetes Any diagnosed cardiovascular (heart) disease or high blood pressure (=160 mmHg systolic and/or =100 mmHg diastolic) Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors) Consumption of a low-carbohydrate dietSmoking or chewing tobacco Known anaemia Regular use of dietary protein and/or amino acid supplements (>3 times per week) Currently involved in a structured progressive resistance training program (>3 times per week) A personal or family history of thrombosis (clots) Any previous motor disorders or inborn errors in muscle and/or lipid metabolism History of kidney disease History of liver disease Pregnant or breastfeeding History of any drug or alcohol abuse in the past two years Claustrophobia Unable to give consent

Design outcomes

Primary

MeasureTime frame
The primary study endpoint is the change in postprandial muscle insulin sensitivity from 0 to 48 hours, measured as the delta forearm glucose uptake (FGU) via the arteriovenous forearm balance technique.

Secondary

MeasureTime frame
Postprandial muscle insulin sensitivity, measured as the temporal response of forearm glucose uptake (FGU) via arteriovenous forearm balance.Forearm amino acid net balance and kinetics (i.e. the rate of appearance and disappearance) measured via the forearm balance technique and stable isotope tracer infusion.Whole-body substrate oxidation (measured via indirect calorimetry).

Countries

Netherlands

Contacts

Public ContactM.L. Dirks

Wageningen Universiteit

marlou.dirks@wur.nl+31317484136

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)